Vivo Capital’s VYNE Therapeutics VYNE Stock Holding History

Vivo Capital’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,049	Closed	-$1.61M	–	65
2021 Q1	$1.61M	Hold	13,049	–	–	0.06%	59
2020 Q4	$1.48M	Sell	13,049 -12,255	-48%	-$1.54M	0.07%	55
2020 Q3	$3.02M	Sell	25,304 -25,305	-50%	-$2.95M	0.17%	56
2020 Q2	$6.3M	Sell	50,609 -2,777	-5%	-$376K	0.45%	43
2020 Q1	$10.3M	Buy	+53,386	New	+$16.7M	0.93%	33
2019 Q3	–	Sell	-55,712	Closed	-$24M	–	28
2019 Q2	$24M	Hold	55,712	–	–	2.25%	13
2019 Q1	$31.5M	Hold	55,712	–	–	3.14%	10
2018 Q4	$16.5M	Hold	55,712	–	–	2.11%	13
2018 Q3	$39.5M	Hold	55,712	–	–	3.98%	8
2018 Q2	$32.6M	Hold	55,712	–	–	4.2%	6
2018 Q1	$151M	Buy	+55,712	New	+$136M	21.35%	1

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Vivo Capital's VYNE Position: Q2 2021 in Review

Vivo Capital sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 13,049 shares — an estimated $1.61M sold.

Vivo Capital first reported a position in VYNE in Q1 2018 and held it in 11 quarters. The position peaked at $151M in Q1 2018. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

Vivo Capital reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
Vivo Capital sold 13,049 VYNE Therapeutics shares in Q2 2021, an estimated $1.61M.
Vivo Capital first reported a position in VYNE Therapeutics in Q1 2018 and held it in 11 quarters.
Vivo Capital's VYNE Therapeutics position peaked at $151M in Q1 2018.
72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.